Publication | Open Access

Differential Androgen Deprivation Therapies with Anti-androgens Casodex/Bicalutamide or MDV3100/Enzalutamide versus Anti-androgen Receptor ASC-J9® Lead to Promotion versus Suppression of Prostate Cancer Metastasis

UrologyOncologyGenitourinary CancerMedicineAnti-androgens Casodex/bicalutamidePharmacotherapyProstatic DiseaseProstate Cancer MetastasisPharmacologyDifferential Androgen DeprivationEndocrine-related Cancer